Individuals B-Premise
receiving I-Premise
duloxetine I-Premise
as I-Premise
their I-Premise
initial I-Premise
5-week I-Premise
treatment I-Premise
reported I-Premise
a I-Premise
mean I-Premise
decrease I-Premise
in I-Premise
average I-Premise
pain I-Premise
of I-Premise
1.06 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.72-1.40 I-Premise
) I-Premise
vs I-Premise
0.34 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.01-0.66 I-Premise
) I-Premise
among I-Premise
those I-Premise
who I-Premise
received I-Premise
placebo I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.513 I-Premise
) I-Premise
. I-Premise

Median O
age O
was O
61.4 O
years O
for O
BT O
and O
59.4 O
for O
RP O
( O
P O
= O
.05 O
) O
. O

The B-Premise
change I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
0.067 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.33 I-Premise
) I-Premise
and I-Premise
strength I-Premise
of I-Premise
external I-Premise
rotation I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.55 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
in I-Premise
the I-Premise
scapula-oriented I-Premise
exercise I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
general I-Premise
exercise I-Premise
and I-Premise
control I-Premise
group I-Premise
. I-Premise

The O
purpose O
of O
this O
pilot O
study O
was O
to O
examine O
the O
effects O
of O
a O
combined O
cardiorespiratory O
and O
resistance O
exercise O
training O
program O
of O
short O
duration O
on O
the O
cardiorespiratory O
fitness O
, O
strength O
endurance O
, O
task O
specific O
functional O
muscle O
capacity O
, O
body O
composition O
and O
quality O
of O
life O
( O
QOL O
) O
in O
women O
breast O
cancer O
survivors O
. O

The O
objective O
of O
this O
study O
is O
to O
evaluate O
whether O
a O
six-week O
supervised O
multimodal O
exercise O
intervention O
, O
adjunct O
to O
chemotherapy O
and O
standard O
care O
, O
can O
reduce O
the O
patient O
's O
CRF O
level O
. O

Grade B-Premise
3/4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
29 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
weekly I-Premise
and I-Premise
34 I-Premise
% I-Premise
of I-Premise
those I-Premise
treated I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.35 I-Premise
) I-Premise
. I-Premise

The B-Premise
observed I-Premise
mean I-Premise
difference I-Premise
in I-Premise
the I-Premise
average I-Premise
pain I-Premise
score I-Premise
between I-Premise
duloxetine I-Premise
and I-Premise
placebo I-Premise
was I-Premise
0.73 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.26-1.20 I-Premise
) I-Premise
. I-Premise

This O
paper O
reports O
the O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
of O
the O
patients O
in O
this O
trial O
. O

To O
assess O
the O
efficacy O
of O
a O
novel O
coloplasty O
colonic O
pouch O
design O
in O
optimizing O
bowel O
function O
after O
ultralow O
anterior O
resection O
. O

Somatostatin B-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
have I-Claim
antimitotic I-Claim
activity I-Claim
in I-Claim
endocrine I-Claim
as I-Claim
well I-Claim
as I-Claim
in I-Claim
a I-Claim
variety I-Claim
of I-Claim
nonendocrine I-Claim
tumors I-Claim
. I-Claim

cryoablation B-Premise
was I-Premise
associated I-Premise
with I-Premise
more I-Premise
acute I-Premise
urinary I-Premise
dysfunction I-Premise
( I-Premise
mean I-Premise
PCI I-Premise
urinary I-Premise
function I-Premise
cryoablation=69.4 I-Premise
";" I-Premise
mean I-Premise
EBRT=90.7 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
which I-Premise
resolved I-Premise
over I-Premise
time I-Premise
. I-Premise

The B-Claim
patient I-Claim
accrual I-Claim
to I-Claim
this I-Claim
trial I-Claim
made I-Claim
its I-Claim
results I-Claim
inconclusive I-Claim
, I-Claim
but O
several O
observations O
are O
notable O
. O

Dose-intensified B-Claim
EC I-Claim
does I-Claim
not I-Claim
provide I-Claim
a I-Claim
measurable I-Claim
therapeutic I-Claim
benefit I-Claim
over I-Claim
CEF I-Claim
as I-Claim
neoadjuvant I-Claim
chemotherapy I-Claim
for I-Claim
unselected I-Claim
locally I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

The B-Premise
5-year I-Premise
biochemical I-Premise
+/- I-Premise
clinical I-Premise
relapse-free I-Premise
and I-Premise
overall I-Premise
survival I-Premise
was I-Premise
55.9 I-Premise
% I-Premise
and I-Premise
85.3 I-Premise
% I-Premise
respectively I-Premise
for I-Premise
all I-Premise
patients I-Premise
, I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
schedules I-Premise
. I-Premise

The O
study O
included O
130 O
patients O
with O
no O
history O
of O
transurethral O
resection O
of O
the O
prostate O
before O
treatment O
, O
who O
had O
brachytherapy O
on O
one O
of O
two O
prospective O
randomized O
trials O
, O
with O
explicitly O
planned O
and O
executed O
urethral-sparing O
techniques O
( O
100-150 O
% O
minimum O
peripheral O
dose O
) O
using O
either O
103Pd O
or O
125I O
for O
clinical O
T1c-T2c O
prostate O
cancer O
. O

There B-Claim
was I-Claim
no I-Claim
significant I-Claim
difference I-Claim
in I-Claim
overall I-Claim
QOL I-Claim
scores I-Claim
between I-Claim
treatment I-Claim
arms I-Claim
or I-Claim
serially I-Claim
. I-Claim

Global B-Premise
QL I-Premise
scores I-Premise
were I-Premise
lower I-Premise
at I-Premise
both I-Premise
1 I-Premise
and I-Premise
6 I-Premise
weeks I-Premise
following I-Premise
treatment I-Premise
for I-Premise
patients I-Premise
treated I-Premise
by I-Premise
SEMSs I-Premise
( I-Premise
mean I-Premise
difference I-Premise
QL I-Premise
index I-Premise
week I-Premise
1=-0.66 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
-0.02 I-Premise
to I-Premise
-1.30 I-Premise
, I-Premise
P=0.04 I-Premise
";" I-Premise
mean I-Premise
difference I-Premise
QL I-Premise
index I-Premise
week I-Premise
6=-1.01 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.30 I-Premise
to I-Premise
-1.72 I-Premise
, I-Premise
P=0.006 I-Premise
) I-Premise
. I-Premise

This O
is O
, O
in O
part O
, O
because O
scales O
and O
measures O
of O
QOL O
are O
still O
relatively O
unfamiliar O
to O
most O
clinicians O
and O
because O
population-based O
reference O
ranges O
are O
lacking O
, O
thus O
making O
clinical O
trial O
results O
difficult O
to O
interpret O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

However B-Claim
, I-Claim
it I-Claim
provided I-Claim
no I-Claim
improvement I-Claim
in I-Claim
PFS I-Claim
or I-Claim
OS I-Claim
compared I-Claim
with I-Claim
flat I-Claim
dosing I-Claim
. I-Claim

Despite O
premature O
trial O
closure O
, O
our O
data O
provided O
valuable O
insights O
. O

Outcome O
parameters O
were O
: O
postoperative O
morbidity O
, O
length O
of O
hospital O
stay O
, O
quality O
of O
life O
, O
long-term O
survival O
, O
and O
local O
recurrences O
. O

An B-Premise
average I-Premise
weight I-Premise
gain I-Premise
in I-Premise
group I-Premise
B I-Premise
contrasted I-Premise
with I-Premise
an I-Premise
average I-Premise
weight I-Premise
loss I-Premise
in I-Premise
group I-Premise
A I-Premise
after I-Premise
four I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
eight I-Premise
weeks I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
non-hematological I-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
Arm I-Premise
B I-Premise
( I-Premise
31 I-Premise
% I-Premise
versus I-Premise
22 I-Premise
% I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
overall I-Premise
remission I-Premise
rate I-Premise
, I-Premise
the I-Premise
rate I-Premise
of I-Premise
complete I-Premise
remission I-Premise
, I-Premise
the I-Premise
median I-Premise
survival I-Premise
and I-Premise
the I-Premise
rate I-Premise
of I-Premise
long-term I-Premise
survival I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
in I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

Response B-Premise
rate I-Premise
was I-Premise
47.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
39.9 I-Premise
% I-Premise
to I-Premise
54.5 I-Premise
% I-Premise
) I-Premise
for I-Premise
gemcitabine I-Premise
plus I-Premise
carboplatin I-Premise
and I-Premise
30.9 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
24.1 I-Premise
% I-Premise
to I-Premise
37.7 I-Premise
% I-Premise
) I-Premise
for I-Premise
carboplatin I-Premise
( I-Premise
P I-Premise
= I-Premise
.0016 I-Premise
) I-Premise
. I-Premise

QOL B-Premise
, I-Premise
except I-Premise
for I-Premise
symptoms I-Premise
of I-Premise
sensory I-Premise
neuropathy I-Premise
and I-Premise
hearing I-Premise
loss I-Premise
, I-Premise
in I-Premise
those I-Premise
treated I-Premise
with I-Premise
chemotherapy I-Premise
returned I-Premise
to I-Premise
baseline I-Premise
by I-Premise
9 I-Premise
months I-Premise
. I-Premise

Study O
patients O
included O
472 O
low-income O
, O
predominantly O
female O
Hispanic O
patients O
with O
cancer O
age O
> O
or= O
18 O
years O
with O
major O
depression O
( O
49 O
% O
) O
, O
dysthymia O
( O
5 O
% O
) O
, O
or O
both O
( O
46 O
% O
) O
. O

The B-Claim
unroofing I-Claim
and I-Claim
marsupialization I-Claim
procedure I-Claim
provides I-Claim
more I-Claim
clinical I-Claim
benefits I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
pilonidal I-Claim
disease I-Claim
than I-Claim
rhomboid I-Claim
excision I-Claim
and I-Claim
Limberg I-Claim
flap I-Claim
and I-Claim
should I-Claim
be I-Claim
considered I-Claim
the I-Claim
procedure I-Claim
of I-Claim
choice I-Claim
. I-Claim

The B-Premise
estimated I-Premise
median I-Premise
overall I-Premise
survival I-Premise
times I-Premise
for I-Premise
RS I-Premise
+ I-Premise
WBRT I-Premise
and I-Premise
S I-Premise
+ I-Premise
WBRT I-Premise
patients I-Premise
were I-Premise
6.2 I-Premise
and I-Premise
2.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
0.53 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
0.20-1.43 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.20 I-Premise
) I-Premise
. I-Premise

The O
study O
was O
designed O
as O
a O
2 O
x O
2 O
factorial O
trial O
. O

Data O
of O
299 O
patients O
were O
available O
for O
evaluation O
. O

The B-Claim
two I-Claim
schedules I-Claim
are I-Claim
equivalent I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
response I-Claim
rate I-Claim
, I-Claim
median I-Claim
time-to-progression I-Claim
and I-Claim
overall I-Claim
survival I-Claim
. I-Claim

Patients B-Premise
carrying I-Premise
the I-Premise
GPX1-CC I-Premise
genotype I-Premise
had I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
decline I-Premise
in I-Premise
the I-Premise
UNISCALE I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
( I-Premise
OR I-Premise
) I-Premise
: I-Premise
7.5 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
total I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Lung I-Premise
score I-Premise
( I-Premise
OR I-Premise
: I-Premise
11.0 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
physical I-Premise
( I-Premise
OR I-Premise
: I-Premise
7.1 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
functional I-Premise
( I-Premise
OR I-Premise
: I-Premise
5.2 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
emotional I-Premise
well-being I-Premise
constructs I-Premise
( I-Premise
OR I-Premise
: I-Premise
23.8 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The O
effectiveness O
of O
a O
Pain O
Education O
Program O
in O
cancer O
patients O
with O
chronic O
pain O
offered O
by O
nurses O
was O
investigated O
in O
a O
randomized O
controlled O
clinical O
trial O
. O

Patients O
were O
randomly O
assigned O
( O
2:1 O
) O
to O
GE O
or O
G O
treatment O
";" O
GE O
arm O
: O
E O
500 O
mg O
p.o O
. O

To O
investigate O
the O
impact O
of O
dietary O
counseling O
or O
nutritional O
supplements O
on O
outcomes O
in O
cancer O
patients O
: O
nutritional O
, O
morbidity O
, O
and O
quality O
of O
life O
( O
QoL O
) O
during O
and O
3 O
months O
after O
radiotherapy O
. O

In O
the O
absence O
of O
an O
overall O
survival O
benefit O
of O
using O
HDC O
for O
high-risk O
breast O
cancer O
patients O
, O
QOL O
studies O
with O
a O
longer O
follow-up O
play O
an O
important O
role O
in O
informing O
the O
complex O
trade-off O
implied O
by O
HDC O
between O
higher O
toxicity O
, O
reduced O
risk O
of O
relapse O
, O
and O
QOL O
decrease O
after O
the O
active O
phase O
of O
treatment O
. O

Treatment B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
despite I-Claim
the I-Claim
fact I-Claim
that I-Claim
most I-Claim
patients I-Claim
suffered I-Claim
from I-Claim
multiple I-Claim
comorbidities I-Claim
and I-Claim
were I-Claim
heavily I-Claim
pretreated I-Claim
. I-Claim

Patients O
with O
progressive O
, O
androgen-independent O
prostate O
cancer O
were O
randomly O
assigned O
to O
one O
of O
two O
treatments O
: O
either O
ketoconazole/doxorubicin O
alternating O
with O
vinblastine/estramustine O
( O
KA/VE O
) O
or O
paclitaxel O
, O
estramustine O
, O
and O
oral O
etoposide O
( O
TEE O
) O
. O

There O
were O
no O
differences O
between O
treatment O
groups O
in O
dimension O
scores O
at O
baseline O
( O
randomization O
) O
. O

Two B-Premise
patients I-Premise
treated I-Premise
with I-Premise
a I-Premise
cumulative I-Premise
dose I-Premise
of I-Premise
MMC I-Premise
of I-Premise
40 I-Premise
mg/m2 I-Premise
developed I-Premise
haemolytic I-Premise
uraemic I-Premise
syndrome I-Premise
warranting I-Premise
the I-Premise
reduction I-Premise
in I-Premise
cumulative I-Premise
MMC I-Premise
dose I-Premise
to I-Premise
28 I-Premise
mg/m2 I-Premise
. I-Premise

Tamoxifen B-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
be I-Claim
more I-Claim
effective I-Claim
and I-Claim
safe I-Claim
than I-Claim
RT I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

Functional O
Assessment O
of O
Cancer O
Therapy O
core O
questionnaire O
( O
FACT-G O
) O
with O
its O
additional O
breast O
cancer O
subscale O
were O
performed O
at O
baseline O
, O
4 O
, O
8 O
, O
and O
12 O
weeks O
after O
NHT O
. O

The B-Claim
treatment I-Claim
choice I-Claim
for I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
esophageal I-Claim
cancer I-Claim
should I-Claim
be I-Claim
between I-Claim
a I-Claim
SEMS I-Claim
or I-Claim
a I-Claim
non-stent I-Claim
treatment I-Claim
after I-Claim
consideration I-Claim
has I-Claim
been I-Claim
given I-Claim
to I-Claim
both I-Claim
patient I-Claim
and I-Claim
tumor I-Claim
characteristics I-Claim
and I-Claim
clinician I-Claim
and I-Claim
patient I-Claim
preferences I-Claim
. I-Claim

Key O
end O
points O
were O
QoL O
at O
18 O
weeks O
, O
measured O
with O
EORTC O
Quality O
of O
Life O
Questionnaire O
( O
QLQ O
) O
-C30 O
and O
QLQ-LC13 O
, O
and O
overall O
survival O
. O

No B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
between I-Premise
arms I-Premise
were I-Premise
noted I-Premise
. I-Premise

However O
, O
we B-Premise
reported I-Premise
a I-Premise
response I-Premise
rate I-Premise
of I-Premise
43.1 I-Premise
and I-Premise
38.6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
MVP I-Premise
and I-Premise
MVC I-Premise
arm I-Premise
( I-Premise
P=0.59 I-Premise
) I-Premise
and I-Premise
a I-Premise
median I-Premise
survival I-Premise
of I-Premise
10.2 I-Premise
and I-Premise
7.2 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
cisplatin I-Premise
and I-Premise
carboplatin I-Premise
arm I-Premise
( I-Premise
P=0.39 I-Premise
) I-Premise
. I-Premise

MA.17 B-Claim
showed I-Claim
that I-Claim
letrozole I-Claim
is I-Claim
extremely I-Claim
well-tolerated I-Claim
relative I-Claim
to I-Claim
placebo I-Claim
. I-Claim

Nineteen B-Premise
percent I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
IFNalpha2a I-Premise
plus I-Premise
13-CRA I-Premise
were I-Premise
progression-free I-Premise
at I-Premise
24 I-Premise
months I-Premise
, I-Premise
compared I-Premise
with I-Premise
10 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
IFNalpha2a I-Premise
alone I-Premise
( I-Premise
P I-Premise
=.05 I-Premise
) I-Premise
. I-Premise

Patients O
were O
randomized O
to O
either O
an O
experimental O
group O
( O
receiving O
the O
PMP O
) O
or O
a O
control O
group O
( O
routine O
care O
) O
. O

Euthyroid B-Premise
patients I-Premise
had I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
one I-Premise
third I-Premise
lower I-Premise
radiation I-Premise
dose I-Premise
to I-Premise
the I-Premise
blood I-Premise
, I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
. I-Premise

Primary O
-- O
patients O
alive O
and O
without O
moderate O
or O
severe O
cough O
, O
chest O
pain O
, O
haemoptysis O
, O
or O
dyspnoea O
six O
months O
from O
randomisation O
, O
as O
recorded O
by O
clinicians O
. O

We O
developed O
Individual O
Meaning-Centered O
Psychotherapy O
( O
IMCP O
) O
to O
address O
the O
need O
for O
brief O
interventions O
targeting O
spiritual O
well-being O
and O
meaning O
for O
patients O
with O
advanced O
cancer O
. O

The O
administration O
of O
the O
smallest O
possible O
amount O
of O
radioiodine O
would O
improve O
care O
. O

Thus O
, O
elderly B-Claim
patients I-Claim
in I-Claim
need I-Claim
of I-Claim
intensified I-Claim
chemotherapy I-Claim
may I-Claim
receive I-Claim
FLOT I-Claim
without I-Claim
compromising I-Claim
patient-reported I-Claim
outcome I-Claim
parameters I-Claim
. I-Claim

Swallowing O
function O
was O
assessed O
with O
the O
Functional O
Oral O
Intake O
Scale O
( O
FOIS O
) O
and O
the O
Performance O
Status O
Scale O
for O
Head O
and O
Neck O
Cancer O
Patients O
( O
PSS-H O
& O
N O
) O
at O
baseline O
, O
immediately O
after O
CRT O
, O
and O
at O
3 O
, O
6 O
, O
9 O
, O
and O
12 O
months O
after O
CRT O
. O

Its B-Claim
leakage I-Claim
rate I-Claim
was I-Claim
lower I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
was I-Claim
better I-Claim
. I-Claim

However O
, O
previous O
studies O
of O
coping O
skills O
training O
( O
CST O
) O
interventions O
have O
not O
been O
tested O
in O
patients O
with O
lung O
cancer O
nor O
have O
systematically O
included O
caregivers O
. O

To O
determine O
1-year O
outcomes O
of O
a O
four-component O
behavioral O
therapy O
( O
BT O
) O
sleep O
intervention O
( O
Individualized O
Sleep O
Promotion O
Plan O
[ O
ISPP O
] O
) O
versus O
a O
healthy O
eating O
control O
( O
HEC O
) O
on O
cancer-related O
fatigue O
in O
women O
receiving O
breast O
cancer O
adjuvant O
chemotherapy O
treatment O
( O
CTX O
) O
. O

We O
investigated O
the O
role O
of O
tamoxifen O
and O
radiotherapy O
( O
RT O
) O
for O
the O
prevention O
and O
treatment O
of O
gynecomastia O
and O
breast O
pain O
during O
adjuvant O
bicalutamide O
monotherapy O
after O
radical O
prostatectomy O
( O
RP O
) O
in O
patients O
with O
prostate O
cancer O
. O

infusion O
and O
5-FU O
, O
850 O
mg/m2 O
s O
i.v O
. O

The B-Premise
incidence I-Premise
of I-Premise
severe I-Premise
neutropenia I-Premise
( I-Premise
34 I-Premise
% I-Premise
versus I-Premise
68 I-Premise
% I-Premise
";" I-Premise
p=0.0001 I-Premise
) I-Premise
and I-Premise
of I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
5 I-Premise
% I-Premise
versus I-Premise
12 I-Premise
% I-Premise
";" I-Premise
p=0.026 I-Premise
) I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
the I-Premise
rate I-Premise
of I-Premise
therapy I-Premise
omissions I-Premise
( I-Premise
10 I-Premise
% I-Premise
versus I-Premise
24 I-Premise
% I-Premise
";" I-Premise
p=0.0037 I-Premise
) I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
weekly I-Premise
VNR/CDDP I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
one I-Premise
. I-Premise

The B-Premise
effects I-Premise
of I-Premise
ATP I-Premise
on I-Premise
body I-Premise
weight I-Premise
, I-Premise
muscle I-Premise
strength I-Premise
, I-Premise
and I-Premise
albumin I-Premise
concentration I-Premise
were I-Premise
especially I-Premise
marked I-Premise
in I-Premise
cachectic I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.0002 I-Premise
, I-Premise
P I-Premise
=.0001 I-Premise
, I-Premise
and I-Premise
P I-Premise
= I-Premise
. I-Premise
1 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
ATP I-Premise
versus I-Premise
no I-Premise
ATP I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
the I-Premise
reduction I-Premise
of I-Premise
incidence/severity I-Premise
of I-Premise
grade I-Premise
1+2 I-Premise
anorexia I-Premise
, I-Premise
nausea/vomiting I-Premise
, I-Premise
xerostomia I-Premise
, I-Premise
and I-Premise
dysgeusia I-Premise
was I-Premise
different I-Premise
: I-Premise
90 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
improved I-Premise
in I-Premise
group I-Premise
1 I-Premise
versus I-Premise
67 I-Premise
% I-Premise
in I-Premise
group I-Premise
2 I-Premise
versus I-Premise
51 I-Premise
% I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

Eighteen B-Premise
patients I-Premise
receiving I-Premise
IFN5 I-Premise
and I-Premise
4 I-Premise
patients I-Premise
receiving I-Premise
IFN1 I-Premise
had I-Premise
dose I-Premise
reductions I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Participants O
were O
randomised O
to O
either O
a O
control O
or O
stretch O
group O
. O

Indecisive O
patients O
were O
randomized O
. O

The O
mean O
age O
was O
52.3 O
vs. O
59.5 O
, O
respectively O
. O

We O
randomly O
assigned O
patients O
with O
locally O
advanced O
prostate O
cancer O
who O
had O
received O
external-beam O
radiotherapy O
plus O
6 O
months O
of O
androgen O
suppression O
to O
two O
groups O
, O
one O
to O
receive O
no O
further O
treatment O
( O
short-term O
suppression O
) O
and O
the O
other O
to O
receive O
2.5 O
years O
of O
further O
treatment O
with O
a O
luteinizing O
hormone-releasing O
hormone O
agonist O
( O
long-term O
suppression O
) O
. O

The B-Premise
ORRs I-Premise
were I-Premise
48.9 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
38.5 I-Premise
% I-Premise
-59.5 I-Premise
% I-Premise
) I-Premise
and I-Premise
58.7 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
47.9 I-Premise
% I-Premise
-68.9 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.117 I-Premise
) I-Premise
with I-Premise
PB I-Premise
and I-Premise
PB+G I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
14.6 I-Premise
months I-Premise
( I-Premise
temozolomide I-Premise
+ I-Premise
radiotherapy I-Premise
) I-Premise
versus I-Premise
12.1 I-Premise
months I-Premise
( I-Premise
radiotherapy I-Premise
alone I-Premise
) I-Premise
. I-Premise

All O
patients O
received O
etoposide O
and O
carboplatin O
every O
3 O
weeks O
for O
up O
to O
six O
cycles O
. O

Subjects O
were O
randomized O
to O
a O
control O
or O
intervention O
group O
";" O
the O
intervention O
was O
performance O
of O
a O
seated O
exercise O
program O
using O
home O
videotape O
three O
times O
per O
week O
for O
four O
cycles O
of O
chemotherapy O
. O

This B-Claim
randomised I-Claim
trial I-Claim
encountered I-Claim
the I-Claim
accrual I-Claim
difficulties I-Claim
and I-Claim
consequent I-Claim
low I-Claim
statistical I-Claim
power I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
interdisciplinary I-Claim
studies I-Claim
drawing I-Claim
from I-Claim
a I-Claim
small I-Claim
eligible I-Claim
population I-Claim
, I-Claim
but O
can O
contribute O
to O
future O
overviews O
on O
the O
management O
of O
solitary O
brain O
metastases O
. O

Annualized O
percentage O
rates O
for O
cardiovascular O
events O
[ O
corrected O
] O
and O
endometrial O
cancers O
[ O
corrected O
] O
were O
below O
national O
rates O
for O
Finland O
and O
those O
reported O
for O
the O
Women O
's O
Health O
Initiative O
. O

Among B-Premise
these I-Premise
32 I-Premise
patients I-Premise
, I-Premise
8 I-Premise
had I-Premise
a I-Premise
partial I-Premise
response I-Premise
( I-Premise
intent-to-treat I-Premise
response I-Premise
rate I-Premise
, I-Premise
20 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
10 I-Premise
( I-Premise
25 I-Premise
% I-Premise
) I-Premise
had I-Premise
stable I-Premise
disease I-Premise
. I-Premise

In B-Claim
cachectic I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
oral I-Claim
melatonin I-Claim
20 I-Claim
mg I-Claim
at I-Claim
night I-Claim
did I-Claim
not I-Claim
improve I-Claim
appetite I-Claim
, I-Claim
weight I-Claim
, I-Claim
or I-Claim
quality I-Claim
of I-Claim
life I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
. I-Claim

In B-Premise
grade I-Premise
IV I-Premise
tumours I-Premise
the I-Premise
corresponding I-Premise
figures I-Premise
were I-Premise
5.1 I-Premise
and I-Premise
3.3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Physician O
and O
nurse O
ratings O
were O
closer O
to O
patients O
' O
ratings O
of O
pain O
for O
trained O
versus O
nutrition O
groups O
( O
P=.04 O
and O
< O
.001 O
, O
respectively O
) O
. O

Beyond O
standard O
toxicity O
end O
points O
, O
physician O
dysphagia O
logs O
( O
PDLs O
) O
, O
daily O
patient O
swallowing O
diaries O
, O
and O
QOL O
( O
EORTC O
QLQ-C30/LC-13 O
) O
were O
also O
collected O
. O

Erlotinib B-Claim
was I-Claim
superior I-Claim
to I-Claim
placebo I-Claim
for I-Claim
survival I-Claim
, I-Claim
progression-free I-Claim
survival I-Claim
, I-Claim
and I-Claim
tumor I-Claim
response I-Claim
rate I-Claim
. I-Claim

Thus B-Claim
, I-Claim
docetaxel-carboplatin I-Claim
represents I-Claim
an I-Claim
alternative I-Claim
first-line I-Claim
chemotherapy I-Claim
regimen I-Claim
for I-Claim
patients I-Claim
with I-Claim
newly I-Claim
diagnosed I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

Cetuximab B-Premise
preserved I-Premise
GHS I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
( I-Premise
-0.2 I-Premise
v I-Premise
-18.1 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Younger B-Premise
patients I-Premise
( I-Premise
< I-Premise
40 I-Premise
years I-Premise
) I-Premise
who I-Premise
received I-Premise
goserelin I-Premise
alone I-Premise
returned I-Premise
to I-Premise
their I-Premise
premenopausal I-Premise
status I-Premise
at I-Premise
6 I-Premise
months I-Premise
after I-Premise
the I-Premise
cessation I-Premise
of I-Premise
therapy I-Premise
, I-Premise
while I-Premise
those I-Premise
who I-Premise
received I-Premise
CMF I-Premise
showed I-Premise
marginal I-Premise
changes I-Premise
from I-Premise
their I-Premise
baseline I-Premise
hot I-Premise
flashes I-Premise
scores I-Premise
. I-Premise

Intervention B-Premise
spouses I-Premise
reported I-Premise
higher I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
more I-Premise
self-efficacy I-Premise
, I-Premise
better I-Premise
communication I-Premise
, I-Premise
and I-Premise
less I-Premise
negative I-Premise
appraisal I-Premise
of I-Premise
caregiving I-Premise
, I-Premise
uncertainty I-Premise
, I-Premise
hopelessness I-Premise
, I-Premise
and I-Premise
symptom I-Premise
distress I-Premise
at I-Premise
4 I-Premise
months I-Premise
compared I-Premise
with I-Premise
controls I-Premise
, I-Premise
and I-Premise
some I-Premise
effects I-Premise
were I-Premise
sustained I-Premise
to I-Premise
8 I-Premise
months I-Premise
and I-Premise
12 I-Premise
months I-Premise
. I-Premise

Patients O
aged O
18-75 O
years O
, O
undergoing O
an O
elective O
laparotomy O
and O
with O
a O
preoperative O
suspicion O
of O
gynecologic O
malignancy O
, O
were O
eligible O
. O

Patients B-Premise
treated I-Premise
with I-Premise
gemcitabine-carboplatin I-Premise
reported I-Premise
significantly I-Premise
faster I-Premise
palliation I-Premise
of I-Premise
abdominal I-Premise
symptoms I-Premise
and I-Premise
a I-Premise
significantly I-Premise
improved I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Subjects O
completed O
visual O
analog O
scales O
, O
the O
FACIT-Fatigue O
Scale O
and O
the O
Short O
Form-36v2 O
after O
surgery O
and O
again O
3 O
to O
6 O
months O
after O
hospital O
discharge O
. O

There B-Premise
were I-Premise
no I-Premise
opportunistic I-Premise
infections I-Premise
. I-Premise

Women B-Premise
with I-Premise
advanced I-Premise
breast I-Premise
cancer I-Premise
randomized I-Premise
to I-Premise
the I-Premise
seated I-Premise
exercise I-Premise
intervention I-Premise
had I-Premise
a I-Premise
slower I-Premise
decline I-Premise
in I-Premise
total I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
and I-Premise
less I-Premise
increase I-Premise
in I-Premise
fatigue I-Premise
scores I-Premise
starting I-Premise
with I-Premise
the I-Premise
third I-Premise
cycle I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

A O
small O
number O
of O
randomized O
controlled O
trials O
have O
examined O
the O
efficacy O
of O
antidepressants O
compared O
to O
that O
of O
a O
placebo O
in O
cancer O
patients O
, O
but O
some O
results O
have O
been O
difficult O
to O
interpret O
due O
to O
a O
heterogeneous O
patient O
group O
. O

Oral B-Claim
doxifluridine I-Claim
with I-Claim
leucovorin I-Claim
shows I-Claim
a I-Claim
comparable I-Claim
therapeutic I-Claim
efficacy I-Claim
to I-Claim
intravenous I-Claim
5-FU I-Claim
regimen I-Claim
with I-Claim
high I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
postoperative I-Claim
adjuvant I-Claim
therapy I-Claim
. I-Claim

Two O
hundred O
one O
( O
83.1 O
% O
) O
participants O
provided O
6-month O
follow-up O
data O
. O

The B-Premise
relative I-Premise
risks I-Premise
of I-Premise
any I-Premise
lymphedema I-Premise
and I-Premise
sensory I-Premise
loss I-Premise
for I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
axillary I-Premise
treatment I-Premise
group I-Premise
at I-Premise
12 I-Premise
months I-Premise
were I-Premise
0.37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.23 I-Premise
to I-Premise
0.60 I-Premise
";" I-Premise
absolute I-Premise
rates I-Premise
: I-Premise
5 I-Premise
% I-Premise
versus I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
0.37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.27 I-Premise
to I-Premise
0.50 I-Premise
";" I-Premise
absolute I-Premise
rates I-Premise
: I-Premise
11 I-Premise
% I-Premise
versus I-Premise
31 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

However B-Claim
, I-Claim
it I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
more I-Claim
inconvenience I-Claim
in I-Claim
wound I-Claim
care I-Claim
and I-Claim
longer I-Claim
healing I-Claim
time I-Claim
than I-Claim
rhomboid I-Claim
excision I-Claim
and I-Claim
Lindberg I-Claim
flap I-Claim
. I-Claim

The O
setting O
was O
in O
a O
hydrotherapy O
pool O
, O
1.2 O
m O
depth O
, O
and O
a O
temperature O
of O
32-33 O
degrees O
capital O
ES O
, O
Cyrillic O
. O

Given O
the O
existing O
evidence O
supporting O
the O
importance O
of O
social O
support O
in O
adjustment O
to O
breast O
cancer O
, O
it B-Claim
seems I-Claim
feasible I-Claim
to I-Claim
suggest I-Claim
that I-Claim
EW I-Claim
may I-Claim
be I-Claim
a I-Claim
cost I-Claim
effective I-Claim
accessible I-Claim
treatment I-Claim
that I-Claim
could I-Claim
be I-Claim
incorporated I-Claim
into I-Claim
the I-Claim
ongoing I-Claim
care I-Claim
of I-Claim
women I-Claim
. I-Claim

In B-Premise
QoL I-Premise
questionnaires I-Premise
, I-Premise
more I-Premise
patients I-Premise
receiving I-Premise
PE I-Premise
reported I-Premise
being I-Premise
upset I-Premise
by I-Premise
hair I-Premise
loss I-Premise
( I-Premise
p I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
and I-Premise
impaired I-Premise
cognitive I-Premise
functioning I-Premise
( I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

Men O
with O
metastatic O
prostate O
cancer O
( O
n O
= O
161 O
) O
were O
randomized O
to O
receive O
either O
daily O
prednisone O
alone O
or O
mitoxantrone O
( O
every O
3 O
weeks O
) O
plus O
prednisone O
. O

The B-Claim
combination I-Claim
of I-Claim
interferon I-Claim
alfa I-Claim
( I-Claim
IFNalpha I-Claim
) I-Claim
and I-Claim
isotretinoin I-Claim
has I-Claim
shown I-Claim
a I-Claim
direct I-Claim
antiproliferative I-Claim
effect I-Claim
on I-Claim
human I-Claim
melanoma I-Claim
cell I-Claim
lines I-Claim
, I-Claim
but B-Claim
it I-Claim
remained I-Claim
unclear I-Claim
whether I-Claim
this I-Claim
combination I-Claim
is I-Claim
more I-Claim
effective I-Claim
than I-Claim
IFNalpha I-Claim
alone I-Claim
in I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
melanoma I-Claim
. I-Claim

More B-Claim
efficient I-Claim
treatment I-Claim
protocol I-Claim
is I-Claim
needed I-Claim
for I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

In O
this O
trial O
, O
histologic B-Claim
confirmation I-Claim
of I-Claim
N2 I-Claim
disease I-Claim
in I-Claim
the I-Claim
surgical I-Claim
and I-Claim
nonsurgical I-Claim
arms I-Claim
eliminated I-Claim
the I-Claim
usual I-Claim
biases I-Claim
from I-Claim
clinical I-Claim
staging I-Claim
. I-Claim

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
TTP I-Premise
) I-Premise
curves I-Premise
according I-Premise
to I-Premise
treatment I-Premise
allocation I-Premise
was I-Premise
documented I-Premise
( I-Premise
P I-Premise
= I-Premise
.411 I-Premise
) I-Premise
. I-Premise

Additional O
end O
points O
included O
overall O
survival O
, O
response O
rate O
( O
RR O
) O
, O
safety O
, O
quality O
of O
life O
, O
and O
translational O
research O
. O

Using O
a O
two-group O
, O
randomized O
controlled O
design O
, O
we O
assigned O
76 O
postmenopausal O
breast O
cancer O
survivors O
with O
at O
least O
one O
severe O
target O
symptom O
either O
to O
the O
intervention O
group O
or O
to O
a O
usual-care O
group O
. O

Nonsignificant B-Premise
differences I-Premise
between I-Premise
groups I-Premise
were I-Premise
found I-Premise
for I-Premise
all I-Premise
unmet I-Premise
supportive I-Premise
care I-Premise
need I-Premise
and I-Premise
quality-of-life I-Premise
scores I-Premise
, I-Premise
change I-Premise
scores I-Premise
, I-Premise
and I-Premise
trends I-Premise
. I-Premise

To O
investigate O
whether O
frequent O
hospital O
follow-up O
in O
the O
first O
year O
after O
breast O
cancer O
treatment O
might O
partly O
be O
replaced O
by O
nurse-led O
telephone O
follow-up O
without O
deteriorating O
health-related O
quality O
of O
life O
( O
HRQoL O
) O
, O
and O
whether O
a O
short O
educational O
group O
programme O
( O
EGP O
) O
would O
enhance O
HRQoL O
. O

Fatigue O
dimensions O
, O
fatigue O
NRS O
score O
, O
interference O
of O
fatigue O
with O
daily O
life O
, O
symptom O
burden O
, O
quality O
of O
life O
, O
anxiety O
, O
and O
depression O
were O
measured O
at O
baseline O
and O
after O
1 O
, O
2 O
, O
and O
3 O
months O
. O

Despite B-Claim
its I-Claim
efficacy I-Claim
in I-Claim
reducing I-Claim
locoregional I-Claim
recurrence I-Claim
, I-Claim
EBRT I-Claim
should I-Claim
be I-Claim
avoided I-Claim
in I-Claim
patients I-Claim
with I-Claim
low- I-Claim
and I-Claim
intermediate-risk I-Claim
EC I-Claim
. I-Claim

WHO B-Premise
grade I-Premise
3 I-Premise
or I-Premise
4 I-Premise
neutropenia I-Premise
and I-Premise
diarrhoea I-Premise
affected I-Premise
46 I-Premise
% I-Premise
and I-Premise
16 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CPT-11 I-Premise
+ I-Premise
LFA I-Premise
5-FU I-Premise
. I-Premise

Although B-Premise
the I-Premise
change I-Premise
in I-Premise
fiber I-Premise
intake I-Premise
between I-Premise
the I-Premise
groups I-Premise
was I-Premise
not I-Premise
significant I-Premise
, I-Premise
there B-Premise
was I-Premise
a I-Premise
trend I-Premise
in I-Premise
the I-Premise
anticipated I-Premise
direction I-Premise
( I-Premise
P=0.083 I-Premise
) I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
well I-Premise
preserved I-Premise
in I-Premise
the I-Premise
euthyroid I-Premise
group I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
, I-Premise
as I-Premise
demonstrated I-Premise
by I-Premise
their I-Premise
lower I-Premise
pretreatment I-Premise
scores I-Premise
on I-Premise
the I-Premise
Billewicz I-Premise
scale I-Premise
for I-Premise
hypothyroid I-Premise
signs I-Premise
and I-Premise
symptoms I-Premise
, I-Premise
27 I-Premise
+/- I-Premise
7 I-Premise
vs. I-Premise
18 I-Premise
+/- I-Premise
4 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
and I-Premise
their I-Premise
significantly I-Premise
higher I-Premise
Short I-Premise
Form-36 I-Premise
Health I-Premise
Assessment I-Premise
Scale I-Premise
scores I-Premise
in I-Premise
five I-Premise
of I-Premise
eight I-Premise
categories I-Premise
. I-Premise

There B-Claim
is I-Claim
a I-Claim
need I-Claim
for I-Claim
further I-Claim
studies I-Claim
so I-Claim
that I-Claim
its I-Claim
effect I-Claim
can I-Claim
be I-Claim
confirmed I-Claim
. I-Claim

Five O
patients O
did O
not O
receive O
any O
chemotherapy O
and O
45 O
received O
only O
one O
cycle O
. O

The B-Premise
median I-Premise
failure I-Premise
free I-Premise
survival I-Premise
was I-Premise
7.9 I-Premise
months I-Premise
in I-Premise
PVI I-Premise
5-FU I-Premise
plus I-Premise
MMC I-Premise
and I-Premise
5.4 I-Premise
months I-Premise
with I-Premise
PVI I-Premise
5-FU I-Premise
alone I-Premise
( I-Premise
P I-Premise
= I-Premise
0.033 I-Premise
) I-Premise
and I-Premise
at I-Premise
one I-Premise
year I-Premise
31.9 I-Premise
% I-Premise
for I-Premise
the I-Premise
combination I-Premise
compared I-Premise
to I-Premise
17.7 I-Premise
% I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
alone I-Premise
. I-Premise

Acupuncture B-Claim
is I-Claim
an I-Claim
effective I-Claim
intervention I-Claim
for I-Claim
managing I-Claim
the I-Claim
symptom I-Claim
of I-Claim
CRF I-Claim
and I-Claim
improving I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Gynecological O
neoplastic O
disease O
progression O
is O
characterized O
by O
specific O
energy O
metabolism O
alterations O
and O
by O
symptoms O
including O
fatigue O
, O
anorexia O
, O
nausea O
, O
anemia O
, O
and O
immunodepression O
, O
which O
result O
in O
a O
cachexia O
syndrome O
and O
a O
marked O
decrease O
in O
patient O
quality O
of O
life O
( O
QoL O
) O
. O

Intention-to-treat O
analyses O
of O
data O
at O
1 O
, O
3 O
, O
6 O
, O
and O
12 O
months O
after O
surgery O
are O
presented O
. O

However O
, O
there B-Claim
was I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
secondary I-Claim
endpoints I-Claim
of I-Claim
clinically I-Claim
assessed I-Claim
OPS I-Claim
and I-Claim
DNA I-Claim
concentration I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
in I-Claim
H I-Claim
& I-Claim
N I-Claim
cancer I-Claim
patients I-Claim
treated I-Claim
with I-Claim
CRT I-Claim
. I-Claim

Similarly B-Premise
, I-Premise
ASES I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
( I-Premise
p=0.001 I-Premise
) I-Premise
improved I-Premise
in I-Premise
both I-Premise
Group I-Premise
I I-Premise
and I-Premise
II I-Premise
without I-Premise
any I-Premise
significant I-Premise
difference I-Premise
between I-Premise
the I-Premise
groups I-Premise
. I-Premise

No B-Claim
appreciable I-Claim
advantage I-Claim
to I-Claim
QoL I-Claim
with I-Claim
TMX I-Claim
was I-Claim
observed I-Claim
. I-Claim

Decision O
boundaries O
were O
to O
accept O
the O
null O
hypothesis O
of O
futility O
if O
the O
test O
statistic O
z O
< O
0.39 O
( O
P O
≥ O
.348 O
) O
and O
reject O
the O
null O
hypothesis O
if O
z O
> O
2.54 O
( O
P O
≤ O
.0056 O
) O
. O

At B-Premise
least I-Premise
one I-Premise
episode I-Premise
of I-Premise
grade I-Premise
3-4 I-Premise
toxicity I-Premise
was I-Premise
observed I-Premise
in I-Premise
27 I-Premise
, I-Premise
25 I-Premise
, I-Premise
38 I-Premise
and I-Premise
47 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
and I-Premise
Tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.016 I-Premise
) I-Premise
. I-Premise

The B-Claim
advantages I-Claim
of I-Claim
a I-Claim
long-lasting I-Claim
improved I-Claim
body I-Claim
image I-Claim
and I-Claim
cosmesis I-Claim
for I-Claim
this I-Claim
relatively I-Claim
young I-Claim
patient I-Claim
population I-Claim
may I-Claim
compensate I-Claim
for I-Claim
the I-Claim
longer I-Claim
operating I-Claim
times I-Claim
and I-Claim
higher I-Claim
costs I-Claim
, I-Claim
particularly I-Claim
for I-Claim
women I-Claim
. I-Claim

Patients O
with O
newly O
diagnosed O
early O
stage O
breast O
cancer O
were O
screened O
for O
depressive O
symptoms O
prior O
to O
the O
initiation O
of O
adjuvant O
therapy O
. O

The O
study O
was O
designed O
to O
detect O
a O
15 O
% O
improvement O
";" O
that O
is O
, O
from O
50 O
% O
to O
65 O
% O
in O
median O
progression-free O
survival O
( O
PFS O
) O
in O
favor O
of O
the O
dose-intensified O
regimen O
. O

A O
total O
of O
157 O
patients O
with O
stage O
IIIB O
or O
IV O
NSCLC O
who O
had O
received O
no O
prior O
chemotherapy O
were O
randomly O
assigned O
to O
receive O
either O
best O
supportive O
care O
alone O
( O
78 O
patients O
) O
or O
paclitaxel O
plus O
supportive O
care O
( O
79 O
patients O
) O
. O

Median O
follow-up O
was O
5.2 O
years O
( O
range O
, O
3.2 O
to O
6.5 O
years O
) O
. O

The B-Premise
response I-Premise
rate I-Premise
was I-Premise
low I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
but I-Premise
superior I-Premise
in I-Premise
the I-Premise
FUP I-Premise
arm I-Premise
: I-Premise
12 I-Premise
% I-Premise
versus I-Premise
0 I-Premise
% I-Premise
( I-Premise
intention-to-treat I-Premise
analysis I-Premise
, I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Eighteen O
patients O
were O
randomized O
to O
GJJ O
and O
21 O
to O
stent O
placement O
. O

A O
randomized O
controlled O
trial O
was O
conducted O
in O
cooperation O
with O
the O
Departments O
of O
General O
Surgery O
and O
Medical O
Psychology O
, O
University O
Hospital O
of O
Hamburg O
, O
Germany O
, O
from O
January O
1991 O
to O
January O
1993 O
. O

Secondary O
end O
points O
were O
overall O
QoL O
, O
psychosocial O
functioning O
, O
cardiovascular O
fitness O
, O
and O
body O
composition O
. O

We O
compared O
quality-adjusted O
life O
expectancy O
( O
the O
overall O
valuation O
of O
the O
health O
of O
the O
patients O
) O
and O
societal O
costs O
for O
patients O
receiving O
either O
single- O
or O
multiple-fraction O
radiotherapy O
. O

Frequent B-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
toxicities I-Premise
for I-Premise
DCF I-Premise
v I-Premise
CF I-Premise
were I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
82 I-Premise
% I-Premise
v I-Premise
57 I-Premise
% I-Premise
) I-Premise
, I-Premise
stomatitis I-Premise
( I-Premise
21 I-Premise
% I-Premise
v I-Premise
27 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrhea I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
8 I-Premise
% I-Premise
) I-Premise
, I-Premise
lethargy I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
14 I-Premise
% I-Premise
) I-Premise
. I-Premise

The O
clinical O
efficacy O
was O
evaluated O
by O
indexes O
including O
KPS O
scores O
, O
QLQ-C30 O
questionnaire O
, O
LC13 O
specific O
scale O
for O
lung O
cancer O
, O
evaluation O
criteria O
for O
TCM O
efficacy O
, O
the O
6-min O
walking O
distance O
, O
and O
body O
weight O
, O
etc O
. O

The B-Premise
median I-Premise
survival I-Premise
was I-Premise
7.8 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
4-11.6 I-Premise
months I-Premise
) I-Premise
. I-Premise

Between O
April O
2010 O
and O
May O
2011 O
, O
patients O
undergoing O
elective O
LCR O
in O
two O
centres O
were O
randomized O
to O
analgesia O
via O
epidural O
or O
WIC O
. O

The O
characteristics O
of O
the O
599 O
patients O
were O
well-balanced O
across O
the O
three O
treatment O
groups O
. O

Different B-Claim
analyses I-Claim
yielded I-Claim
slightly I-Claim
different I-Claim
conclusions I-Claim
but O
, O
in B-Claim
general I-Claim
, I-Claim
the I-Claim
QOL I-Claim
analyses I-Claim
were I-Claim
concordant I-Claim
and I-Claim
showed I-Claim
that I-Claim
patients I-Claim
on I-Claim
DOX I-Claim
alone I-Claim
had I-Claim
fewer I-Claim
disease I-Claim
and I-Claim
treatment I-Claim
related I-Claim
adverse I-Claim
events I-Claim
and I-Claim
better I-Claim
QOL I-Claim
. I-Claim

Mean O
age O
was O
58 O
± O
10 O
years O
, O
57 O
% O
were O
female O
, O
and O
65 O
% O
were O
given O
palliative O
chemotherapy O
. O

bolus O
( O
arm O
A O
) O
";" O
TOM O
, O
3 O
mg/m2 O
i.v O
. O

HRQOL B-Claim
and I-Claim
AEs I-Claim
were I-Claim
similar I-Claim
with I-Claim
exemestane I-Claim
and I-Claim
anastrozole I-Claim
. I-Claim

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
42 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
( I-Premise
11 I-Premise
months I-Premise
v I-Premise
9.1 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.03 I-Premise
) I-Premise
and I-Premise
TFS I-Premise
( I-Premise
15 I-Premise
months I-Premise
v I-Premise
11 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
were I-Premise
superior I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
fludarabine I-Premise
. I-Premise

The O
trial O
was O
stopped O
for O
futility O
at O
interim O
analysis O
. O

One O
group O
was O
treated O
with O
DC/CIK O
immunobiological O
cancer O
therapy O
, O
and O
the O
other O
was O
taken O
as O
a O
control O
group O
. O

In B-Premise
the I-Premise
whole I-Premise
population I-Premise
of I-Premise
patients I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
patients I-Premise
with I-Premise
a I-Premise
PS I-Premise
of I-Premise
0-1 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
Cox I-Premise
model I-Premise
, I-Premise
the I-Premise
relative I-Premise
risk I-Premise
of I-Premise
death I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
was I-Premise
0.70 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
= I-Premise
0.51 I-Premise
to I-Premise
0.95 I-Premise
) I-Premise
";" I-Premise
the B-Premise
disease I-Premise
also I-Premise
progressed I-Premise
more I-Premise
slowly I-Premise
in I-Premise
patients I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
. I-Premise

Few O
intervention O
programs O
assist O
patients O
and O
their O
family O
caregivers O
to O
manage O
advanced O
cancer O
and O
maintain O
their O
quality O
of O
life O
( O
QOL O
) O
. O

Overall B-Premise
, I-Premise
patients I-Premise
receiving I-Premise
goserelin I-Premise
alone I-Premise
showed I-Premise
a I-Premise
marked I-Premise
improvement I-Premise
or I-Premise
less I-Premise
deterioration I-Premise
in I-Premise
QOL I-Premise
measures I-Premise
over I-Premise
the I-Premise
first I-Premise
6 I-Premise
months I-Premise
than I-Premise
those I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CMF I-Premise
. I-Premise

The O
impact O
of O
psychotherapeutic O
support O
on O
survival O
for O
patients O
with O
gastrointestinal O
cancer O
undergoing O
surgery O
was O
studied O
. O

The O
study O
was O
conducted O
in O
the O
palliative O
care O
and O
hospice O
ward O
of O
a O
public O
hospital O
in O
Hong O
Kong O
. O

After O
2 O
weeks O
of O
baseline O
assessment O
, O
all O
participants O
received O
a O
consultation O
plus O
either O
oral O
homeopathic O
medicine O
or O
placebo O
, O
assessed O
every O
4 O
weeks O
for O
16 O
weeks O
. O

EORTC-QLQ O
and O
ASES-tests O
were O
performed O
to O
assess O
the O
quality O
of O
life O
before O
and O
after O
6 O
week-treatment O
. O

Treatment O
effect O
was O
assessed O
using O
paired O
t-test O
. O

Adjusted B-Premise
for I-Premise
baseline I-Premise
score I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
demographic I-Premise
covariates I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
showed I-Premise
an I-Premise
estimated I-Premise
improvement I-Premise
at I-Premise
six I-Premise
weeks I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
of I-Premise
-6.6 I-Premise
points I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-12.3 I-Premise
to I-Premise
-0.9 I-Premise
, I-Premise
P=0.02 I-Premise
";" I-Premise
effect I-Premise
size=0.33 I-Premise
, I-Premise
0.04 I-Premise
to I-Premise
0.61 I-Premise
) I-Premise
. I-Premise

Only B-Claim
the I-Claim
combined I-Claim
intervention I-Claim
yielded I-Claim
effects I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
outcomes I-Claim
, I-Claim
and I-Claim
these I-Claim
were I-Claim
limited I-Claim
to I-Claim
anxiety I-Claim
and I-Claim
depression I-Claim
. I-Claim

We B-Claim
propose I-Claim
that I-Claim
VEGF I-Claim
expression I-Claim
levels I-Claim
in I-Claim
MPE I-Claim
could I-Claim
serve I-Claim
as I-Claim
a I-Claim
prognostic I-Claim
marker I-Claim
for I-Claim
bevacizumab I-Claim
therapy I-Claim
. I-Claim

To O
assess O
the O
safety O
, O
tolerability O
and O
efficacy O
of O
abatacept O
in O
patients O
with O
rheumatoid O
arthritis O
( O
RA O
) O
who O
had O
failed O
anti-tumour O
necrosis O
factor O
( O
TNF O
) O
therapy O
and O
were O
switched O
to O
abatacept O
directly O
or O
after O
completing O
washout O
. O

The B-Claim
study I-Claim
fails I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
of I-Claim
dl-alpha I-Claim
tocopheryl I-Claim
acetate I-Claim
plus I-Claim
pentoxifylline I-Claim
in I-Claim
patients I-Claim
with I-Claim
arm I-Claim
lymphoedema I-Claim
following I-Claim
axillary I-Claim
surgery I-Claim
and I-Claim
lymphatic I-Claim
radiotherapy I-Claim
, I-Claim
nor I-Claim
does I-Claim
it I-Claim
suggest I-Claim
any I-Claim
benefits I-Claim
of I-Claim
these I-Claim
drugs I-Claim
in I-Claim
radiation-induced I-Claim
induration I-Claim
( I-Claim
fibrosis I-Claim
) I-Claim
in I-Claim
the I-Claim
breast I-Claim
, I-Claim
chest I-Claim
wall I-Claim
, I-Claim
pectoral I-Claim
fold I-Claim
, I-Claim
axilla I-Claim
or I-Claim
supraclavicular I-Claim
fossa I-Claim
. I-Claim

The B-Premise
rate I-Premise
of I-Premise
recurrence I-Premise
was I-Premise
9/74 I-Premise
( I-Premise
12.1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
6/92 I-Premise
( I-Premise
6.5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.937 I-Premise
) I-Premise
. I-Premise

Fatigue O
is O
a O
frequent O
problem O
after O
surgical O
treatment O
of O
solid O
tumours O
. O

We O
describe O
analyses O
of O
data O
for O
patient-reported O
pain O
and O
functional O
status O
in O
a O
preplanned O
interim O
analysis O
of O
a O
phase O
3 O
trial O
. O

The B-Premise
HgB I-Premise
responders I-Premise
( I-Premise
irrespective I-Premise
of I-Premise
treatment I-Premise
arm I-Premise
) I-Premise
had I-Premise
a I-Premise
mean I-Premise
change I-Premise
in I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy I-Premise
( I-Premise
FACT I-Premise
) I-Premise
fatigue I-Premise
score I-Premise
from I-Premise
a I-Premise
baseline I-Premise
of I-Premise
+5.1 I-Premise
compared I-Premise
with I-Premise
-2.1 I-Premise
for I-Premise
the I-Premise
nonresponders I-Premise
( I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
. I-Premise

Symptom B-Premise
distress I-Premise
was I-Premise
significantly I-Premise
worse I-Premise
for I-Premise
the I-Premise
RP+RT I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
RP I-Premise
alone I-Premise
arm I-Premise
, O
but B-Premise
the I-Premise
treatment I-Premise
arms I-Premise
did I-Premise
not I-Premise
differ I-Premise
with I-Premise
respect I-Premise
to I-Premise
other I-Premise
general I-Premise
measures I-Premise
of I-Premise
HRQL I-Premise
. I-Premise

No O
patient O
received O
antiretroviral O
therapy O
. O

Few O
intervention O
studies O
have O
been O
conducted O
to O
help O
couples O
manage O
the O
effects O
of O
prostate O
cancer O
and O
maintain O
their O
quality O
of O
life O
. O

At O
baseline O
and O
12 O
weeks O
, O
we O
used O
the O
Brief O
Fatigue O
Inventory O
( O
BFI O
) O
and O
Fatigue O
Severity O
Scale O
( O
FSS O
) O
as O
primary O
outcomes O
and O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
( O
HADS O
) O
and O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
for O
secondary O
outcomes O
. O

At B-Premise
the I-Premise
2-month I-Premise
follow-up I-Premise
assessment I-Premise
, I-Premise
the I-Premise
improvements I-Premise
observed I-Premise
for I-Premise
the I-Premise
IMCP I-Premise
group I-Premise
were I-Premise
no I-Premise
longer I-Premise
significantly I-Premise
greater I-Premise
than I-Premise
those I-Premise
observed I-Premise
for I-Premise
the I-Premise
TM I-Premise
group I-Premise
. I-Premise

Data O
were O
extracted O
from O
the O
database O
of O
a O
prospective O
randomized O
controlled O
trial O
that O
included O
patients O
with O
resectable O
mid O
or O
lower O
thoracic O
esophageal O
cancers O
. O

Compared B-Premise
with I-Premise
MA I-Premise
, I-Premise
there I-Premise
were I-Premise
similar I-Premise
or I-Premise
greater I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
TRSS I-Premise
, I-Premise
and I-Premise
QOL I-Premise
with I-Premise
EXE I-Premise
. I-Premise

The B-Premise
surviving I-Premise
fraction I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
based I-Premise
on I-Premise
Kaplan-Meier I-Premise
analysis I-Premise
. I-Premise

Treatment O
arms O
were O
compared O
using O
differences O
of O
least O
squares O
mean O
( O
LSM O
) O
changes O
from O
baseline O
and O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
at O
each O
timepoint O
and O
overall O
. O

L-T4 O
was O
initiated O
in O
both O
groups O
after O
thyroidectomy O
. O

Other B-Premise
analyzed I-Premise
QOL I-Premise
parameters I-Premise
favored I-Premise
the I-Premise
group I-Premise
receiving I-Premise
placebo I-Premise
but B-Premise
were I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
after I-Premise
adjustment I-Premise
for I-Premise
multiple I-Premise
testing I-Premise
. I-Premise

However O
, O
intraoperative B-Premise
blood I-Premise
loss I-Premise
and I-Premise
postoperative I-Premise
hospital I-Premise
stay I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
( I-Premise
Student I-Premise
t-test I-Premise
) I-Premise
. I-Premise

Cycles O
were O
repeated O
as O
rapidly O
as O
possible O
. O

Caregivers O
and O
patients O
are O
adversely O
affected O
. O

However B-Premise
, I-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
in I-Premise
the I-Premise
high-dose I-Premise
group I-Premise
( I-Premise
19 I-Premise
v I-Premise
14 I-Premise
weeks I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

Patients O
with O
bone O
metastasis-related O
pain O
at O
Numeric O
Rating O
Scale O
≥4 O
were O
enrolled O
to O
this O
randomized O
placebo-controlled O
trial O
. O

PFS B-Premise
was I-Premise
significantly I-Premise
longer I-Premise
for I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
( I-Premise
n I-Premise
= I-Premise
362 I-Premise
) I-Premise
than I-Premise
250 I-Premise
mg I-Premise
( I-Premise
n I-Premise
= I-Premise
374 I-Premise
) I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
= I-Premise
0.80 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.68 I-Premise
to I-Premise
0.94 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
, I-Premise
corresponding I-Premise
to I-Premise
a I-Premise
20 I-Premise
% I-Premise
reduction I-Premise
in I-Premise
risk I-Premise
of I-Premise
progression I-Premise
. I-Premise

There O
were O
no O
differences O
in O
the O
intraoperative O
time O
and O
hospital O
stay O
. O

Only B-Premise
1 I-Premise
patient I-Premise
in I-Premise
each I-Premise
group I-Premise
had I-Premise
acute I-Premise
nonhematologic I-Premise
toxicity I-Premise
greater I-Premise
than I-Premise
Grade I-Premise
3 I-Premise
( I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
vaginal I-Premise
bleeding I-Premise
, I-Premise
mood I-Premise
alteration I-Premise
, I-Premise
or I-Premise
low I-Premise
energy I-Premise
. I-Premise

Follow-up O
time O
ranged O
from O
14 O
to O
56 O
months O
( O
median O
, O
33 O
months O
) O
. O

MRI O
scans O
at O
baseline O
, O
6 O
months O
, O
and O
5 O
years O
were O
independently O
interpreted O
by O
two O
radiologists O
. O

Although O
CP O
has O
recently O
been O
shown O
to O
be O
feasible O
in O
patients O
, O
there O
is O
no O
randomized O
controlled O
trial O
comparing O
bowel O
function O
with O
the O
J-pouch O
. O

Participants O
had O
significant O
disease O
load O
with O
65 O
% O
of O
participants O
presenting O
with O
two O
or O
more O
regions O
affected O
by O
bone O
metastases O
and O
an O
average O
Gleason O
score O
of O
8.2±0.9 O
. O

Two O
hundred O
eighty-nine O
patients O
were O
assessable O
for O
response O
, O
and O
99 O
responders O
were O
assessable O
for O
response O
duration O
( O
RD O
) O
. O

More B-Premise
than I-Premise
90 I-Premise
% I-Premise
of I-Premise
patients I-Premise
did I-Premise
not I-Premise
require I-Premise
a I-Premise
dose I-Premise
increase I-Premise
and I-Premise
28.7 I-Premise
% I-Premise
had I-Premise
a I-Premise
dose I-Premise
reduction I-Premise
. I-Premise

Between O
February O
2003 O
and O
April O
2009 O
, O
40 O
patients O
were O
considered O
eligible O
, O
22 O
consented O
to O
randomisation O
and O
21 O
were O
analysed O
( O
11 O
RS O
+ O
WBRT O
, O
10 O
S O
+ O
WBRT O
) O
. O

Seventy O
patients O
completed O
the O
4 O
weeks O
period O
of O
study O
. O

A B-Premise
7 I-Premise
% I-Premise
response I-Premise
rate I-Premise
was I-Premise
observed I-Premise
with I-Premise
topotecan I-Premise
( I-Premise
complete I-Premise
response I-Premise
, I-Premise
2 I-Premise
% I-Premise
";" I-Premise
partial I-Premise
response I-Premise
, I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Patients B-Premise
with I-Premise
a I-Premise
PS I-Premise
of I-Premise
0-1 I-Premise
and I-Premise
a I-Premise
resected I-Premise
tumor I-Premise
had I-Premise
the I-Premise
significantly I-Premise
longest I-Premise
survival I-Premise
both I-Premise
in I-Premise
EEP-L I-Premise
treated I-Premise
patients I-Premise
and I-Premise
in I-Premise
all I-Premise
evaluable I-Premise
patients I-Premise
in I-Premise
the I-Premise
two I-Premise
studies I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
PB I-Premise
experienced I-Premise
more I-Premise
improvement I-Premise
in I-Premise
total I-Premise
FACT-B I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Breast I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.021 I-Premise
) I-Premise
, I-Premise
FACT-B I-Premise
Social/Family I-Premise
Well-being I-Premise
( I-Premise
P I-Premise
= I-Premise
.041 I-Premise
) I-Premise
, I-Premise
and I-Premise
Breast I-Premise
Cancer-Additional I-Premise
Concerns I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
scores I-Premise
than I-Premise
patients I-Premise
treated I-Premise
with I-Premise
PB+G I-Premise
. I-Premise

ES B-Premise
scores I-Premise
and I-Premise
CES-D I-Premise
scores I-Premise
were I-Premise
similar I-Premise
in I-Premise
all I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Thirty O
days O
after O
the O
treatment O
, O
efficacy O
, O
toxicity O
, O
and O
adverse O
effects O
were O
assessed O
in O
both O
study O
groups O
. O

All O
statistical O
tests O
were O
two-sided O
. O

Climacteric B-Premise
symptoms I-Premise
remained I-Premise
significantly I-Premise
below I-Premise
baseline I-Premise
values I-Premise
after I-Premise
dosage I-Premise
reduction I-Premise
";" I-Premise
some B-Premise
symptoms I-Premise
recurred I-Premise
after I-Premise
discontinuation I-Premise
of I-Premise
ccHRT I-Premise
. I-Premise

Participants O
were O
randomised O
to O
follow-up O
care O
as O
usual O
( O
3-monthly O
outpatient O
clinic O
visits O
) O
, O
nurse-led O
telephone O
follow-up O
, O
or O
the O
former O
strategies O
combined O
with O
an O
educational O
group O
programme O
. O

Administration O
amounts O
of O
nausea O
and O
pain O
medications O
were O
compared O
with O
a O
Two-Way O
ANOVA O
with O
One O
Repeated O
Measure O
resulting O
in O
no O
significant O
differences O
between O
groups O
and O
medications O
, O
F O
( O
1 O
, O
51 O
) O
= O
0.03 O
";" O
p O
> O
.05 O
. O

Improvements B-Premise
in I-Premise
favor I-Premise
of I-Premise
PPT I-Premise
were I-Premise
also I-Premise
found I-Premise
for I-Premise
the I-Premise
following I-Premise
secondary I-Premise
outcomes I-Premise
: I-Premise
fatigue I-Premise
dimensions I-Premise
" I-Premise
reduced I-Premise
activity I-Premise
" I-Premise
and I-Premise
" I-Premise
reduced I-Premise
motivation I-Premise
, I-Premise
" I-Premise
fatigue I-Premise
NRS I-Premise
, I-Premise
symptom I-Premise
burden I-Premise
, I-Premise
interference I-Premise
of I-Premise
fatigue I-Premise
with I-Premise
daily I-Premise
life I-Premise
, I-Premise
and I-Premise
anxiety I-Premise
( I-Premise
all I-Premise
P I-Premise
≤ I-Premise
.03 I-Premise
) I-Premise
. I-Premise

Controls O
had O
no O
prophylactic O
exercises O
and O
were O
referred O
for O
swallowing O
treatment O
after O
completion O
of O
CRT O
if O
indicated O
. O

We O
designed O
a O
trial O
to O
investigate O
the O
effects O
of O
epoetin O
alfa O
therapy O
on O
the O
QOL O
of O
anemic O
patients O
with O
advanced O
non-small-cell O
carcinoma O
of O
the O
lung O
( O
NSCLC O
) O
. O

Mean B-Premise
dominant I-Premise
fibroid I-Premise
diameter I-Premise
was I-Premise
7.6 I-Premise
± I-Premise
3.0 I-Premise
, I-Premise
5.8 I-Premise
± I-Premise
2.9 I-Premise
, I-Premise
and I-Premise
5 I-Premise
± I-Premise
2.9 I-Premise
cm I-Premise
at I-Premise
baseline I-Premise
, I-Premise
6 I-Premise
months I-Premise
, I-Premise
and I-Premise
5 I-Premise
years I-Premise
. I-Premise

After O
16 O
of O
the O
first O
65 O
randomized O
patients O
experienced O
febrile O
neutropenia O
( O
FN O
) O
, O
the O
doses O
were O
reduced O
to O
DOX O
40 O
mg/m O
( O
2 O
) O
on O
day O
1 O
and O
VNB O
20 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
versus O
DOX O
60 O
mg/m O
( O
2 O
) O
on O
day O
1 O
. O

No O
prospective O
comparison O
with O
nitrosourea-based O
chemotherapy O
exists O
. O

A O
hot O
flash O
score O
was O
calculated O
at O
each O
time O
point O
. O

( O
From O
April O
1996 O
to O
November O
1997 O
, O
191 O
of O
the O
350 O
targeted O
patients O
were O
randomly O
assigned O
. O
) O

The O
results O
were O
analyzed O
using O
a O
linear O
mixed-effects O
model O
. O

With O
100 O
patients O
and O
77 O
events O
, O
the O
study O
had O
80 O
% O
power O
to O
detect O
an O
improvement O
in O
median O
progression-free O
survival O
from O
4 O
to O
6.5 O
months O
( O
one-sided O
, O
10 O
% O
-level O
test O
) O
. O

infusion O
and O
5-FU O
, O
800 O
mg/m2 O
i.v O
. O

The O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
, O
where O
available O
, O
the O
EuroQOL O
EQ-5D O
questionnaire O
were O
administered O
every O
8 O
weeks O
from O
baseline O
until O
progression O
and O
then O
every O
3 O
months O
. O

or O
i.v O
. O

Twenty-eight O
cancer O
survivors O
with O
insomnia O
were O
randomly O
assigned O
to O
either O
an O
Internet O
insomnia O
intervention O
( O
n O
= O
14 O
) O
or O
to O
a O
waitlist O
control O
group O
( O
n O
= O
14 O
) O
. O

We O
compared O
fulvestrant O
500 O
mg O
regimen O
with O
the O
approved O
dose O
of O
fulvestrant O
250 O
mg O
per O
month O
for O
treatment O
of O
postmenopausal O
women O
with O
estrogen O
receptor-positive O
advanced O
breast O
cancer O
who O
experienced O
progression O
after O
prior O
endocrine O
therapy O
. O

Ten O
years O
of O
treatment O
planned O
. O

However O
, O
there O
is O
a O
wide O
heterogeneity O
in O
the O
clinical O
impact O
of O
hypothyroidism O
. O

Seventy-two O
women O
with O
breast O
cancer O
experiencing O
three O
or O
more O
hot O
flashes O
per O
day O
were O
randomly O
assigned O
to O
receive O
either O
TRUE O
or O
sham O
acupuncture O
. O

Estramustine O
was O
given O
orally O
, O
280 O
mg O
twice O
daily O
, O
as O
soon O
as O
the O
diagnosis O
was O
established O
, O
during O
and O
after O
the O
radiotherapy O
for O
a O
period O
of O
in O
total O
3 O
months O
. O

Treatment O
arms O
were O
compared O
using O
the O
stratified O
log-rank O
test O
and O
Cox O
proportional O
hazards O
model O
adjusted O
for O
trial O
stratum O
( O
visceral O
metastases O
, O
previous O
hormone O
sensitivity O
) O
, O
age O
, O
sex O
, O
race O
, O
baseline O
global O
health O
status O
score O
and O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
, O
prognostic O
risk O
factors O
, O
and O
treatment O
history O
. O

The O
association O
between O
intervention O
and O
survival O
was O
also O
assessed O
. O

